Author

admin

Browsing

/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/

finlay minerals ltd. (TSXV: FYL) (OTCQB: FYMNF ) (‘Finlay’ or the ‘Company’) is pleased to announce that it intends to complete a non-brokered private placement (the ‘ Private Placement ‘) consisting of the issuance of any combination of: (i) common shares of the Company to be issued on a flow-through basis under the Income Tax Act ( Canada ) (each, a ‘ FT Share ‘) at a price of $0.11 per FT Share, and (ii) non-flow-through units of the Company (each, a ‘ NFT Unit ‘) at a price of $0.10 per NFT Unit, for aggregate gross proceeds to the Company of up to $1,000,000 . The Private Placement is subject to a minimum offering amount of $500,000 to be raised through any combination of FT Shares and NFT Units.

Each NFT Unit will be comprised of one non-flow-through common share of the Company (each, a ‘ NFT Share ‘) and one non-flow-through common share purchase warrant (a ‘ Warrant ‘). Each Warrant will be exercisable by the holder thereof to acquire one NFT Share at an exercise price of $0.20 per NFT Share for a period of two years from the date of issuance of the Warrant (the ‘ Warrant Expiry Date ‘), subject to acceleration. The Warrant Expiry Date may, at the Company’s sole discretion, be accelerated if at any time following the Closing Date (as defined herein), the common shares of the Company trade at a daily volume-weighted average trading price above $0.30 per common share for a period of 30 consecutive trading days on the TSX Venture Exchange (the ‘ TSXV ‘) or on such other stock exchange where the majority of the trading occurs (the ‘ Trading Target ‘) and the Company provides notice to the Warrant holders by way of press release announcing that such Trading Target has been achieved, provided that the accelerated expiry date of the Warrants falls on the earlier of (unless exercised by the holder prior to such date) (the ‘ Accelerated Expiry Date ‘): (i) the 30th day after the Company provides notice to the Warrant holders of its intention to accelerate the Warrant Expiry Date; and (ii) the Warrant Expiry Date. The failure of the Company to give notice in respect of a Trading Target will not preclude the Company from giving notice of any subsequent Trading Target. All Warrants that remain unexercised following the Accelerated Expiry Date shall immediately expire and all rights of holders of such Warrants shall be terminated without any compensation to such holders.

The Company intends to use the gross proceeds of the Private Placement for exploration of the Company’s SAY, JJB and Silver Hope properties, and for general working capital purposes. The Company will use the gross proceeds from the issuance of FT Shares to incur ‘Canadian exploration expenses’ and qualify as ‘flow-through mining expenditures’, as such terms are defined in the Income Tax Act ( Canada ).

Subject to compliance with applicable regulatory requirements, the Private Placement is being conducted pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and in reliance on the Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption . The securities issued to purchasers in the Private Placement will not be subject to a hold period under applicable Canadian securities laws. There is an offering document related to the Private Placement that can be accessed under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.finlayminerals.com . Prospective investors should read this offering document before making an investment decision.

The closing of the Private Placement is expected to occur on or about June 9, 2025 (the ‘ Closing Date ‘). The closing of the Private Placement is subject to certain closing conditions, including the approval of the TSXV. The Company may pay finder’s fees in cash and securities to certain arm’s length finders engaged in connection with the Private Placement, subject to the approval of the TSXV.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the United States Securities Act of 1933 , as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder.

About finlay minerals ltd.

Finlay is a TSXV company focused on exploration for base and precious metal deposits through the advancement of its ATTY, PIL, JJB, SAY and Silver Hope Properties; these properties host copper-gold porphyry and gold-silver epithermal targets within different porphyry districts of northern and central BC. Each property is located in areas of recent development and porphyry discoveries with the advantage of hosting the potential for new discoveries.

Finlay trades under the symbol ‘FYL’ on the TSXV and under the symbol ‘FYMNF’ on the OTCQB. For further information and details, please visit the Company’s website at www.finlayminerals.com

On behalf of the Board of Directors,

Robert F. Brown ,
Executive Chairman of the Board & Director

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain ‘forward-looking information’ and ‘forward-looking statements’ (collectively, ‘forward-looking statements’) within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as ‘expect’, ‘plan’, ‘anticipate’, ‘project’, ‘target’, ‘potential’, ‘schedule’, ‘forecast’, ‘budget’, ‘estimate’, ‘intend’ or ‘believe’ and similar expressions or their negative connotations, or that events or conditions ‘will’, ‘would’, ‘may’, ‘could’, ‘should’ or ‘might’ occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, the terms and completion of the Private Placement, raising the minimum and maximum amounts of the Private Placement, the payment of finder’s fees and issuance of finder’s securities, the anticipated closing date and the planned use of proceeds for the Private Placement. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the ability to obtain regulatory approval for the Private Placement, the state of equity markets in Canada and other jurisdictions, market prices, exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay’s proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements,   and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law.

SOURCE finlay minerals ltd.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/26/c7629.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com

Bold Ventures Inc. (TSXV: BOL) (the ‘Company’ or ‘Bold’) is pleased to announce that the offering of its non-brokered private placement first announced on April 11th will be increased by up to $150,000. The Company will be offering up to 9,000,000 working capital units (the ‘WC Units’) of the Company at a price of $0.05 per WC Unit for up to $450,000, and up to 10,000,000 Flow Through units (the ‘FT Units’) at a price of $0.06 per FT Unit for up to $600,000, both of which constitute the ‘Offering.’

The Offering has also been extended for up to a further thirty (30) days.

The Company closed the third tranche of the Offering with subscriptions for 4,530,000 FT Units and 200,000 WC Units for gross proceeds of $281,800, for a total of 8,031,333 FT Units and 6,000,000 WC Units for gross proceeds of $781,879.98 for the Offering so far.

The Offering will remain open until the earlier of the sale of the remaining WC Units and FT Units and June 23, 2025.

The Company paid cash finder’s fees of $14,830.00 and issued 245,5000 compensation warrants (the ‘Compensation Warrants‘) to eligible finders. Each Compensation Warrant entitles the holder to acquire one common share of the Company at $0.08 until November 23, 2026.

The securities issued in the third tranche are subject to a hold period expiring on September 24, 2025.

Insider Subscriptions

Two insiders subscribed for 250,000 FT Units for proceeds of $15,000 on the closing of the third tranche of the Offering. The insider private placements are exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 (‘MI 61-101‘) by virtue of the exemptions contained in sections 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company to be issued to the insiders does not exceed 25% of its market capitalization.

The Offering

Each WC Unit comprises one (1) common share of the Company priced at $0.05 and one full common share purchase warrant (a ‘WC Warrant‘) entitling the holder to acquire one (1) common share at a price of $0.06 until two years (24 months) following the closing of the Offering. The proceeds from the WC Units will be used for general working capital, property maintenance, exploration and expenses of the offering.

Each FT Unit comprises one common share of the Company priced at $0.06 and one half (1/2) of a common share purchase warrant. One full common share purchase warrant (a ‘FT Warrant’) and $0.08 will acquire an additional common share until eighteen (18) months following the closing of the Offering. The proceeds from the sale of the FT Units will be used for exploration work that qualifies for Canadian Exploration Expenses (CEE).

Investor News Network Agreement

Bold Ventures management believes our suite of Battery, Critical and Precious Metals exploration projects are an ideal combination of exploration potential meeting future demand. Our target commodities are comprised of: Copper (Cu), Nickel (Ni), Lead (Pb), Zinc (Zn), Gold (Au), Silver (Ag), Platinum (Pt), Palladium (Pd) and Chromium (Cr). The Critical Metals list and a description of the Provincial and Federal electrification plans are posted on the Bold website here.

About Bold Ventures Inc.

The Company explores for Precious, Battery and Critical Metals in Canada. Bold is exploring properties located in active gold and battery metals camps in the Thunder Bay and Wawa regions of Ontario. Bold also holds significant assets located within and around the emerging multi-metals district dubbed the Ring of Fire region, located in the James Bay Lowlands of Northern Ontario.

For additional information about Bold Ventures and our projects please visit boldventuresinc.com or contact us at 416-864-1456 or email us at info@boldventuresinc.com.

‘Bruce A MacLachlan’ ‘David B Graham’
Bruce MacLachlan David Graham
President and COO CEO

 
Direct line: (705) 266-0847
Email: bruce@boldventuresinc.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: This Press Release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words ‘may’, ‘would’, ‘could’, ‘will’, ‘intend’, ‘plan’, ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’ and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities. Should one or more of these risks and uncertainties, such actual results of current exploration programs, the general risks associated with the mining industry, the price of gold and other metals, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward-looking statements.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION
IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253357

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

Here’s a quick recap of the crypto landscape for Monday (May 26) as of 9:00 a.m. UTC.

Get the latest insights on Bitcoin, Ethereum and altcoins, along with a round-up of key cryptocurrency market news.

Bitcoin and Ethereum price update

Bitcoin (BTC) was priced at US$107,203 as markets closed, down 2.2 percent in 24 hours. The day’s range for the cryptocurrency brought a low of US$106,802 and a new all-time high of US$110,078.

Bitcoin performance, May 26, 2025.

Chart via TradingView

Ethereum (ETH) finished the trading day at US$2,554.49, a 2.0 percent decrease over the past 24 hours. The cryptocurrency reached an intraday low of US$2,493.61 and saw a daily high of US$2,586.26.

Altcoin price update

  • Solana (SOL) closed at US$177.55, up 3.4 percent over 24 hours. SOL experienced a low of US$169.90 and a high of US$178.34.
  • XRP is trading at US$2.29, reflecting a 1.6 percent increase over 24 hours. The cryptocurrency reached a daily low of US$2.28 and a high of US$2.35.
  • Sui (SUI) is priced at US$3.59, showing an increaseof 1.6 percent over the past 24 hours. It achieved a daily low of US$3.47 and a high of US$3.65.
  • Cardano (ADA) is trading at US$0.7576, up 3.1 percent over the past 24 hours. Its lowest price of the day was US$0.7361, and it reached a high of US$0.7748.

Today’s crypto news to know

Could soaring debt send Bitcoin to US$1 million by 2030? Market heavyweights think so

Some of the most prominent voices in finance are sounding bullish on Bitcoin, predicting it could breach the US$1 million mark by the end of the decade.

ARK Invest CEO Cathie Wood sees BTC hitting US$1.5 million by 2030 in a high-conviction ‘bull case’ scenario, attributing this surge to institutional adoption and Bitcoin’s unique monetary properties.

Similarly, financial author Robert Kiyosaki has echoed the million-dollar prediction, linking it to surging U.S. debt and potential economic collapse, which he says will push investors toward safe-haven assets like Bitcoin, gold, and silver.

“I strongly believe, by 2035, that one Bitcoin will be over US$1 million, Gold will be US$30,000, and silver US$3,000 a coin,” Kiyosaki posted on X.

“We have been quite bullish over the last five or six weeks. We have been bearish coming out of the Trump inauguration in February, but we turned quite bullish,” 10x Research CEO Markus Thielen similarly posted on the same platform.

If momentum continues, 2025 could mark Bitcoin’s most aggressive bull run to date. Still, volatility remains a key wildcard, especially as political and macroeconomic dynamics evolve.

Pakistan dedicates 2,000 MW to Bitcoin mining and AI infrastructure

Pakistan’s finance ministry announced that it will allocate 2,000 megawatts of electricity to power bitcoin mining and AI data centers.

The initiative is spearheaded by the government-backed Pakistan Crypto Council and is part of a national plan to monetize surplus electricity and modernize the economy.

With excess generation capacity and rising solar adoption straining the grid, the country is seeking new ways to use otherwise wasted energy. Officials say the plan will not only alleviate grid imbalances but also create tech-focused jobs and attract foreign investment.

This marks one of the most ambitious state-backed crypto infrastructure moves by a developing country to date.

If successful, it could help position Pakistan as a regional hub for digital assets and artificial intelligence development. It also comes amid wider energy reforms aimed at revitalizing the nation’s troubled power sector.

Trader Behind US$1 billion Bitcoin bet goes all-in on PEPE memecoin

Pseudonymous trader “James Wynn,” better known as “moonpig” on the decentralized exchange Hyperliquid, has become one of the most talked-about crypto traders after flipping from a billion-dollar Bitcoin long to a US$1 million leveraged bet on memecoin PEPE.

Just days ago, Wynn closed a record US$1.2 billion BTC long with a US$17.5 million loss, then doubled down on a US$1 billion short using 40x leverage, netting US$3 million as BTC dipped.

After posting about US$25 million in total profit from his trading spree, Wynn announced he’s walking away from perpetuals altogether.

His latest PEPE trade, however, has already gained US$500,000 as the token jumped 6 percent in just a few hours.

The on-chain transparency of Wynn’s trades has captivated Crypto Twitter, turning him into a meme icon himself.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Nuclear energy and uranium stocks surged after US President Donald Trump signed a sweeping set of executive orders aimed at overhauling nuclear policy and accelerating the deployment of next-generation reactors.

The orders, which were signed on May 23 with industry leaders present, mark the Trump administration’s most aggressive push yet to redefine nuclear power as central to America’s energy, technological and defense future.

“We’re also talking about the big plants — the very, very big, the biggest,” Trump said during the signing ceremony at the Oval Office. “We’re going to be doing them also, but I think our focus today is the smaller module.”

Oklo (NYSE:OKLO) and NuScale (NYSE:SMR), both of which are small modular reactor (SMR) developers, soared by 23 and 19 percent, respectively. Constellation Energy (NASDAQ:CEG), the nation’s largest nuclear operator, gained 2 percent, while Canada-based uranium producer Cameco (TSX:CCO,NYSE:CCJ)rose by nearly 11 percent.

US uranium-focused firms Uranium Energy (NYSEAMERICAN:UEC), Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) and Centrus Energy (NYSEAMERICAN:LEU) saw gains ranging from 19.6 to 24.2 percent.

The Global X Uranium ETF (ARCA:URA), which tracks uranium-related equities, jumped more than 11.6 percent.

Fast-tracking nuclear reactor licenses

One of Trump’s orders instructs the Nuclear Regulatory Commission (NRC) to finalize decisions on reactor license applications within 18 months and overhaul its current regulatory framework.

The directive calls for internal reorganization, overseen in part by the Office of Management and Budget and the Department of Government Efficiency, better known as DOGE.

Analysts warn this could weaken the NRC’s operational independence.

Though the order does not formally place the NRC under White House supervision, critics point to a prior executive order in February as evidence of a broader strategy to curtail regulatory autonomy.

Despite potential concerns over staffing and capacity, the Trump administration is clear in its expectations — it wants to see a rapid licensing process to facilitate commercial and defense-related nuclear buildouts.

AI and national security integration

Titled ‘Deploying Nuclear Reactor Technologies for National Security,” another of Trump’s orders calls for a nuclear reactor to be operational at a domestic military base by September 30, 2028.

Through this directive, the president has tasked the Department of Energy (DOE) with designating artificial intelligence (AI) data centers co-located at DOE sites as “critical defense facilities,” with their nuclear power sources categorized as “defense critical electric infrastructure.” The goal is to ensure stable, high-density, dispatchable power for both military readiness and the growing energy needs of AI computing infrastructure.

This order also instructs the Department of Defense and the DOE to explore categorical exclusions under the National Environmental Policy Act for reactor construction on federal sites, an attempt to further expedite deployment.

Reviving fuel supply chains and recycling

The administration is also attempting to reboot the US nuclear fuel cycle.

The DOE has been directed to release 20 metric tons of high-assay low-enriched uranium (HALEU) into a commercial fuel bank for private sector use. This move marks a significant policy shift in that it directs the DOE to identify usable plutonium and uranium in its inventory for potential recycling into nuclear fuel — a move that bucks decades of US reluctance toward commercial reprocessing due to proliferation risks.

There are currently no commercial nuclear fuel recycling facilities in the US, and the order’s provisions could encourage the creation of a domestic market for recycled fuel. This work could become especially important as international competitors like China and Russia continue to develop similar capabilities.

International push and export diplomacy

Secretary of State Marco Rubio has been directed to lead negotiations under Section 123 of the Atomic Energy Act to facilitate nuclear technology exports. Within 90 days, the administration has been told to develop strategies to increase financing and technical assistance for civil nuclear projects in partner countries.

The goal is to disrupt what the administration sees as growing foreign control over the nuclear industry — 87 percent of new reactor builds globally rely on non-US designs, and most of the world’s nuclear fuel supply originates abroad.

“By instructing the Department of State and other agencies to aggressively pursue export opportunities, this Order will strengthen our relationships with our allies and disrupt potential industry control by adversaries,” the White House said in a fact sheet released alongside last week’s executive orders.

Domestic workforce and reactor testing

Another order, “Reinvigorating the Nuclear Industrial Base,” calls for measures to support workforce development, modernize waste management strategies and complete or restart dormant nuclear construction projects.

It also mandates an updated report on the fuel cycle and related infrastructure — effectively a follow up to the 2020 “Strategy to Restore American Nuclear Energy Leadership” published under Trump’s first term.

While the order “Reforming Nuclear Reactor Testing at the DOE” stops short of demanding new test facilities, it instructs the national laboratory system to expand capacity for testing new reactors, potentially reviving interest in the Versatile Test Reactor project, which was canceled due to congressional defunding during the Biden administration.

Observers note that much of the Trump administration’s current nuclear policy builds upon previous initiatives — such as the 2017 Nuclear Energy Innovation and Capabilities Act, and Biden-era investments in HALEU and SMRs.

However, the new executive orders notably reflect a deliberate departure from longstanding caution around regulatory independence and nuclear fuel recycling.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Gold Price Surge Hits $3,385 Amid Trade Tensions

The gold price surge continued on April 21, 2025, as gold hit a record high of $3,385 per ounce. This milestone came amid a weakening U.S. dollar and renewed global trade tensions. Investors are increasingly turning to gold as a safe-haven asset, signaling market uncertainty and shifting investment strategies.

Gold Price Increase Driven by Dollar Weakness

The U.S. dollar index fell sharply, hitting its lowest level since January 2024. A weaker dollar typically boosts gold prices, as it makes the metal more attractive to international buyers. This contributed significantly to the ongoing gold price surge seen in recent weeks.

In addition, economic data indicating slower growth in key global markets has prompted investors to reduce their exposure to riskier assets. Gold’s long-standing reputation as a hedge against economic uncertainty has once again proven true.

Trade Tensions Fuel Demand for Safe-Haven Assets

Ongoing trade friction between major economies—particularly the U.S. and China—has triggered market anxiety. Announcements related to new tariffs and supply chain risks are further motivating the shift from equities to gold. This environment is ideal for a gold price surge to gain momentum.

Analysts Predict Continued Gold Price Growth

Market analysts suggest that the upward trend is far from over. If inflation persists and interest rates remain steady or fall, the gold price could climb even higher. Some predict that the next psychological barrier of $3,500 per ounce may soon be tested.

As the global economic landscape continues to evolve, gold is expected to remain a central pillar in investor portfolios. Whether as a hedge against inflation or a response to geopolitical unrest, the gold price surge is being closely monitored by financial experts.

Source: Yahoo Finance

Related: Market Insights | Commodity News

The post Gold Price Surge Hits $3,385 Amid Trade Tensions appeared first on FinanceBrokerage.

BNB Price Surge Leads Crypto Gains as Bitcoin Climbs

The BNB price surge on April 21, 2025, stole the spotlight as Binance Coin jumped over 3.2% to cross the $600 mark. This move came as Bitcoin soared past $87,000, reigniting investor interest in altcoins. The bullish wave didn’t stop with BNB—SOL and XRP also made strong moves, reflecting a positive trend across the cryptocurrency market.

BNB Price Surge Driven by Token Burn and Momentum

Fueling the BNB price surge was Binance’s recent $1 billion token burn, which reduced the circulating supply. Additionally, increased trading volumes and renewed faith in Binance’s ecosystem helped BNB regain upward momentum. Investors are optimistic that Binance’s expansion and focus on compliance could drive long-term growth.

SOL Rally and XRP Breakout Add to Market Optimism

Solana (SOL) saw a 10.2% rally, breaking above the $135 resistance level with strong volume and technical confirmation. XRP, on the other hand, climbed past $2.10, setting the stage for a potential breakout above $2.15. These moves indicate bullish setups that are gaining attention from both traders and long-term holders.

Bitcoin Reinforces Its Role as Digital Gold

Bitcoin’s rise above $87,000 reflects renewed demand for a digital safe-haven. With increasing global economic uncertainty and inflation concerns, many investors view Bitcoin as “digital gold.” This sentiment is spilling over into altcoins, triggering the current crypto rally.

Conclusion and Market Outlook

The BNB price surge highlights growing investor confidence in altcoins. Alongside Bitcoin’s strength, tokens like SOL and XRP are enjoying increased attention. If this trend continues, more gains could be ahead for altcoin markets. Investors should monitor resistance levels and trading volumes closely for signs of sustained momentum.

Source: Yahoo Finance

Related: Crypto Updates | Market Trends

The post BNB Price Surge Leads Crypto Gains as Bitcoin Climbs appeared first on FinanceBrokerage.

Buy Bitcoin Under $100K Before The Next Bull Run

The opportunity to buy Bitcoin under $100K may not last much longer. On April 21, 2025, Bitcoin (BTC) traded just below the $100,000 mark, a price level many analysts believe could be the last stop before a massive new rally begins. With institutional adoption rising and macroeconomic pressures easing, the case for long-term BTC growth is strengthening.

Why Now Might Be the Time to Buy Bitcoin Under $100K

Market experts point to several factors fueling the bullish sentiment. Firstly, Bitcoin’s halving event earlier this year significantly reduced block rewards, cutting daily supply by half. Historically, halving events have preceded major bull runs. Secondly, growing interest from ETFs and institutional players is creating steady buying pressure. Lastly, declining inflation and improved global liquidity conditions are encouraging investment in risk assets like Bitcoin.

According to Bitwise CIO Matt Hougan, “It’s not too late to buy Bitcoin under $100K. This could be one of the last best opportunities before we see a surge well beyond six figures.”

Long-Term Outlook for BTC Investors

Looking ahead, many analysts predict that Bitcoin could exceed $150,000 by the end of the year. While this isn’t guaranteed, trends in institutional adoption, limited supply, and rising use cases for Bitcoin suggest that prices may continue climbing.

Although short-term volatility persists, long-term investors remain focused on fundamentals. If history repeats itself, buying Bitcoin at sub-$100K levels may prove to be a decision rewarded in the coming cycle.

Final Thoughts

If you’ve been on the sidelines, now could be your moment to enter the market. The chance to buy Bitcoin under $100K might not last much longer. As always, do your research and consider your financial goals before investing.

Source: Yahoo Finance

Related: Bitcoin News | Crypto Analysis

The post Buy Bitcoin Under $100K Before The Next Bull Run appeared first on FinanceBrokerage.

Trump’s Fed Criticism Sparks Investor Concerns

The recent spotlight on Trump’s Fed Criticism has sparked unease among investors and financial analysts alike. President Donald Trump’s repeated public attacks on Federal Reserve Chair Jerome Powell have amplified concerns over the central bank’s independence. As a result, markets have reacted with volatility, and investor sentiment has taken a noticeable hit.

Market Reactions to Political Pressure

Wall Street’s response to Trump’s Fed Criticism was swift. Major stock indices, including the S&P 500 and Nasdaq, posted losses amid uncertainty over future monetary policy decisions. Investors fear that political attempts to sway the Federal Reserve’s agenda may undermine its objectivity. If monetary policy is dictated by short-term political goals rather than long-term economic data, the implications could be severe for inflation, interest rates, and overall economic health.

Why Federal Reserve Independence Matters

One of the cornerstones of a stable economy is a politically neutral central bank. Trump’s Fed Criticism has called that neutrality into question. The Federal Reserve must be able to act without external pressure to maintain credibility in the eyes of global markets. Political interference could compromise its ability to control inflation or manage unemployment rates effectively.

Investor Sentiment and Future Outlook

Investor confidence remains fragile. Many market participants have shifted assets into safer investments such as gold and U.S. treasuries, seeking shelter from potential turmoil. Economic advisors stress the importance of maintaining clear, data-driven policy guidance, especially as the U.S. navigates ongoing trade issues and inflation concerns.

In the coming weeks, the Federal Reserve’s actions will be closely watched. Should Trump’s Fed Criticism intensify, it could further erode market stability and investor trust in U.S. monetary policy.

Source: Yahoo Finance

 

The post Trump’s Fed Criticism Sparks Investor Concerns appeared first on FinanceBrokerage.

Oil Prices Rebound After Trump’s Criticism of Fed Chair Powell

On April 22, 2025, oil prices rebound experienced a modest rebound following a significant drop the previous day. The initial decline was triggered by President Donald Trump’s renewed criticism of Federal Reserve Chair Jerome Powell, which unsettled financial markets and raised concerns about the central bank’s independence.

Market Reaction to Political Commentary

President Trump’s comments on Monday intensified investor fears regarding the Federal Reserve’s autonomy in setting monetary policy. The criticism led to a broad sell-off in equities and commodities, with oil prices bearing the brunt of the market’s anxiety.

Short-Covering Leads to Price Recovery

Despite the initial plunge, oil prices rebound edged higher on Tuesday as investors engaged in short-covering. Brent crude futures rose 0.5% to $66.62 per barrel, while West Texas Intermediate (WTI) crude for May delivery increased by 1% to $63.73 per barrel. The more actively traded WTI June contract also gained 0.7% to $62.84 per barrel.

Ongoing Economic Concerns

Market participants remain cautious amid ongoing fears of a potential recession linked to U.S. tariff policies and concerns over Federal Reserve independence. These factors have increased worries about the U.S. economy and crude demand. Additionally, progress in U.S.-Iran nuclear deal talks has eased supply concerns, potentially impacting oil prices further.

As the situation evolves, investors will closely monitor geopolitical developments and central bank communications to assess the potential long-term impacts on the energy markets.

Source: BloomBurg

The post Oil Prices Rebound After Trump’s Criticism of Powell appeared first on FinanceBrokerage.

It took six months, countless hours on hold and intervention from state regulators before Sue Cover says she finally resolved an over $1,000 billing dispute with UnitedHealthcare in 2023.

Cover, 46, said she was overbilled for emergency room visits for her and her son, along with a standard ultrasound. While Cover said her family would eventually have been able to pay the sum, she said it would have been a financial strain on them.

Cover, a San Diego benefits advocate, said she had conversations with UnitedHealthcare that “felt like a circular dance.” Cover said she picked through dense policy language and fielded frequent calls from creditors. She said the experience felt designed to exhaust patients into submission.

“It sometimes took my entire day of just sitting on the phone, being on hold with the hospital or the insurance company,” Cover said.

Cover’s experience is familiar to many Americans. And it embodies rising public furor toward insurers and in particular UnitedHealthcare, the largest private health insurer in the U.S., which has become the poster child for problems with the U.S. insurance industry and the nation’s sprawling health-care system.

The company and other insurers have faced backlash from patients who say they were denied necessary care, providers who say they are buried in red tape and lawmakers who say they are alarmed by its vast influence.

UnitedHealthcare in a statement said it is working with Cover’s provider to “understand the facts of these claims.” The company said it is “unfortunate that CNBC rushed to publish this story without allowing us and the provider adequate time to review.” CNBC provided the company several days to review Cover’s situation before publication.

Andrew Witty, CEO of UnitedHealthcare’s company, UnitedHealth Group, stepped down earlier this month for what the company called “personal reasons.” Witty had led the company through the thick of public and investor blowback. The insurer also pulled its 2025 earnings guidance this month, partly due to rising medical costs, it said.

UnitedHealth Group is by far the biggest company in the insurance industry by market cap, worth nearly $275 billion. It controls an estimated 15% of the U.S. health insurance market, serving more than 29 million Americans, according to a 2024 report from the American Medical Association. Meanwhile, competitors Elevance Health and CVS Health control an estimated 12% of the market each.

It’s no surprise that a company with such a wide reach faces public blowback. But the personal and financial sensitivity of health care makes the venom directed at UnitedHealth unique, some experts told CNBC.

Shares of UnitedHealth Group are down about 40% this year following a string of setbacks for the company, despite a temporary reprieve sparked in part by share purchases by company insiders. In the last month alone, UnitedHealth Group has lost nearly $300 billion of its $600 billion market cap following Witty’s exit, the company’s rough first-quarter earnings and a reported criminal probe into possible Medicare fraud.

In a statement about the investigation, UnitedHealth Group said, “We stand by the integrity of our Medicare Advantage program.”

Over the years, UnitedHealthcare and other insurers have also faced numerous patient and shareholder lawsuits and several other government investigations.

UnitedHealth Group is also contending with the fallout from a February 2024 ransomware attack on Change Healthcare, a subsidiary that processes a significant portion of the country’s medical claims.

More recently, UnitedHealthcare became a symbol for outrage toward insurers following the fatal shooting of its CEO, Brian Thompson, in December. Thompson’s death reignited calls to reform what many advocates and lawmakers say is an opaque industry that puts profits above patients.

The problems go deeper than UnitedHealth Group: Insurers are just one piece of what some experts call a broken U.S. health-care system, where many stakeholders, including drugmakers and pharmacy benefit managers, are trying to balance patient care with making money. Still, experts emphasized that insurers’ cost-cutting tactics — from denying claims to charging higher premiums — can delay or block crucial treatment, leave patients with unexpected bills, they say, or in some cases, even mean the difference between life and death.

In a statement, UnitedHealthcare said it is unfortunate that CNBC appears to be drawing broad conclusions based on a small number of anecdotes.”

Frustration with insurers is a symptom of a broader problem: a convoluted health-care system that costs the U.S. more than $4 trillion annually.

U.S. patients spend far more on health care than people anywhere else in the world, yet have the lowest life expectancy among large, wealthy countries, according to the Commonwealth Fund, an independent research group. Over the past five years, U.S. spending on insurance premiums, out-of-pocket co-payments, pharmaceuticals and hospital services has also increased, government data show.

While many developed countries have significant control over costs because they provide universal coverage, the U.S. relies on a patchwork of public and private insurance, often using profit-driven middlemen to manage care, said Howard Lapin, adjunct professor at the University of Illinois Chicago School of Law.

But the biggest driver of U.S. health spending isn’t how much patients use care — it’s prices, said Richard Hirth, professor of health management and policy at the University of Michigan.

There is “unbelievable inflation of the prices that are being charged primarily by hospitals, but also drug companies and other providers in the system,” said Sabrina Corlette, co-director of the Center on Health Insurance Reforms at Georgetown University.

Lapin said factors such as overtreatment, fraud, health-care consolidation and administrative overhead raise costs for payers and providers, who then pass those on through higher prices. U.S. prescription drug prices are also two to three times higher than those in other developed countries, partly due to limited price regulation and pharmaceutical industry practices such as patent extensions.

While patients often blame insurers, the companies are only part of the problem. Some experts argue that eliminating their profits wouldn’t drastically lower U.S. health-care costs.

Still, UnitedHealthcare and other insurers have become easy targets for patient frustration — and not without reason, according to industry experts.

Their for-profit business model centers on managing claims to limit payouts, while complying with regulations and keeping customers content. That often means denying services deemed medically unnecessary, experts said. But at times, insurers reject care that patients need, leaving them without vital treatment or saddled with hefty bills, they added.

Insurers use tools such as deductibles, co-pays, and prior authorization — or requiring approval before certain treatments — to control costs. Industry experts say companies are increasingly relying on artificial intelligence to review claims, and that can sometimes lead to inaccurate denials.

“It’s all part of the same business model — to avoid paying as many claims as possible in a timely fashion,” said Dylan Roby, an affiliate at the UCLA Center for Health Policy Research.

While other private U.S. insurers employ many of the same tactics, UnitedHealth Group appears to have faced the most public backlash due to its size and visibility.

UnitedHealth Group’s market value dwarfs the sub-$100 billion market caps of competitors such as CVS, Cigna and Elevance. UnitedHealth Group booked more than $400 billion in revenue in 2024 alone, up from roughly $100 billion in 2012.

It has expanded into many parts of the health-care system, sparking more criticism of other segments of its business — and the company’s ability to use one unit to benefit another.

UnitedHealth Group grew by buying smaller companies and building them into its growing health-care business. The company now serves nearly 150 million people and controls everything from insurance and medical services to sensitive health-care data.

UnitedHealth Group owns a powerful pharmacy benefit manager, or PBM, called Optum Rx, which gives it even more sway over the market.

PBMs act as middlemen, negotiating drug rebates on behalf of insurers, managing lists of drugs covered by health plans and reimbursing pharmacies for prescriptions. But lawmakers and drugmakers accuse them of overcharging plans, underpaying pharmacies and failing to pass savings on to patients.

Owning a PBM gives UnitedHealth Group control over both supply and demand, Corlette said. Its insurance arm influences what care is covered, while Optum Rx determines what drugs are offered and at what price. UnitedHealth Group can maximize profits by steering patients to lower-cost or higher-margin treatments and keeping rebates, she said.

The company’s reach goes even further, Corlette added: Optum Health now employs or affiliates with about 90,000 doctors — nearly 10% of U.S. physicians — allowing UnitedHealth Group to direct patients to its own providers and essentially pay itself for care.

A STAT investigation last year found that UnitedHealth uses its physicians to squeeze profits from patients. But the company in response said its “providers and partners make independent clinical decisions, and we expect them to diagnose and document patient information completely and accurately in compliance with [federal] guidelines.”

Other insurers, such as CVS and Cigna, also own large PBMs and offer care services. But UnitedHealth Group has achieved greater scale and stronger financial returns.

“I think the company is certainly best in class when it comes to insurers, in terms of providing profits for shareholders,” said Roby. “But people on the consumer side probably say otherwise when it comes to their experience.”

No one knows exactly how often private insurers deny claims, since they aren’t generally required to report that data. But some analyses suggest that UnitedHealthcare has rejected care at higher rates than its peers for certain types of plans.

A January report by nonprofit group KFF found that UnitedHealthcare denied 33% of in-network claims across Affordable Care Act plans in 20 states in 2023, one of the highest rates among major insurers. CVS denied 22% of claims across 11 states, and Cigna denied 21% in eight states.

UnitedHealth did not respond to a request for comment on that report. But in December, the company also pushed back on public criticism around its denial rates, saying it approves and pays about 90% of claims upon submission. UnitedHealthcare’s website says the remaining 10% go through an additional review process. The company says its claims approval rate stands at 98% after that review.

In addition, UnitedHealth Group is facing lawsuits over denials. In November, families of two deceased Medicare Advantage patients sued the company and its subsidiary, alleging it used an AI model with a “90% error rate” to deny their claims. UnitedHealth Group has argued it should be dismissed from the case because the families didn’t complete Medicare’s appeals process.

A spokesperson for the company’s subsidiary, NaviHealth, also previously told news outlets that the lawsuit “has no merit” and that the AI tool is used to help providers understand what care a patient may need. It does not help make coverage decisions, which are ultimately based on the terms of a member’s plan and criteria from the Centers for Medicare & Medicaid Services, the spokesperson said.

Meanwhile, the reported Justice Department criminal probe outlined by the Wall Street Journal targets the company’s Medicare Advantage business practices. In its statement, the company said the Justice Department has not notified it about the reported probe, and called the newspaper’s reporting “deeply irresponsible.”

Inside the company, employees say customers and workers alike face hurdles.

One worker, who requested anonymity for fear of retaliation, said UnitedHealthcare’s provider website often includes doctors listed as in-network or accepting new patients when they’re not, leading to frequent complaints. Management often replies that it’s too difficult to keep provider statuses up to date, the person said.

UnitedHealthcare told CNBC it believes “maintaining accurate provider directories is a shared responsibility among health plans and providers,” and that it “proactively verifies provider data on a regular basis.” The vast majority of all inaccuracies are due to errors or lack of up-to-date information submitted by providers, the company added.

Emily Baack, a clinical administrative coordinator at UMR, a subsidiary of UnitedHealthcare, criticized the length of time it can take a provider to reach a real support worker over the phone who can help assess claims or prior authorization requests. She said the company’s automated phone system can misroute people’s calls or leave them waiting for a support person for over an hour.

But Baack emphasized that similar issues occur across all insurance companies.

She said providers feel compelled to submit unnecessary prior authorization requests out of fear that claims won’t be paid on time. Baack said that leads to a massive backlog of paperwork on her end and delays care for patients.

UnitedHealthcare said prior authorization is “an important checkpoint” that helps ensure members are receiving coverage for safe and effective care.

The company noted it is “continually taking action to simplify and modernize the prior authorization process.” That includes reducing the number of services and procedures that require prior authorization and exempting qualified provider groups from needing to submit prior authorization requests for certain services.

While UnitedHealthcare is not the only insurer facing criticism from patients, Thompson’s killing in December reinforced the company’s unique position in the public eye. Thousands of people took to social media to express outrage toward the company, sharing examples of their own struggles.

The public’s hostile reaction to Thompson’s death did not surprise many industry insiders.

Alicia Graham, co-founder and chief operating officer of the startup Claimable, said Thompson’s murder was “a horrible crime.” She also acknowledged that anger has been bubbling up in various online health communities “for years.”

Claimable is one of several startups trying to address pain points within insurance. It’s not an easy corner of the market to enter, and many of these companies, including Claimable, have been using the AI boom to their advantage.

Claimable, founded in 2024, said it helps patients challenge denials by submitting customized, AI-generated appeal letters on their behalf. The company can submit appeals for conditions such as migraines and certain pediatric and autoimmune diseases, though Graham said it is expanding those offerings quickly.

Many patients aren’t aware that they have a right to appeal, and those who do can spend hours combing through records to draft one, Graham said. If patients are eligible to submit an appeal letter through Claimable, she said they can often do so in minutes. Each appeal costs users $39.95 plus shipping, according to the company’s website.

“A lot of patients are afraid, a lot of patients are frustrated, a lot of patients are confused about the process, so what we’ve tried to do is make it all as easy as possible,” Graham told CNBC.

Some experts have warned about the possibility of health-care “bot wars,” where all parties are using AI to try to gain an edge.

Mike Desjadon, CEO of the startup Anomaly, said he’s concerned about the potential for an AI arms race in the sector, but he remains optimistic. Anomaly, founded in 2020, uses AI to help providers determine what insurers are and aren’t paying for in advance of care, he said.

“I run a technology company and I want to win, and I want our customers to win, and that’s all very true, but at the same time, I’m a citizen and a patient and a husband and a father and a taxpayer, and I just want health care to be rational and be paid for appropriately,” Desjadon told CNBC.

Dr. Jeremy Friese, founder and CEO of the startup Humata Health, said patients tend to interact with insurers only once something goes wrong, which contributes to their frustrations. Requirements such as prior authorization can be a “huge black box” for patients, but they’re also cumbersome for doctors, he said.

Friese said his business was inspired by his work as an interventional radiologist. In 2017, he co-founded a prior-authorization company called Verata Health, which was acquired by the now-defunct health-care AI startup Olive. Friese bought back his technology and founded his latest venture, Humata, in 2023.

Humata uses AI to automate prior authorization for all specialties and payers, Friese said. The company primarily works with medium and large health systems, and it announced a $25 million funding round in June.

“There’s just a lot of pent-up anger and angst, frankly, on all aspects of the health-care ecosystem,” Friese told CNBC.

UnitedHealth Group also set a grim record last year that did little to help public perception. The company’s subsidiary Change Healthcare suffered a cyberattack that affected around 190 million Americans, the largest reported health-care data breach in U.S. history.

Change Healthcare offers payment and revenue cycle management tools, as well as other solutions, such as electronic prescription software. In 2022, it merged with UnitedHealth Group’s Optum unit, which touches more than 100 million patients in the U.S.

In February 2024, a ransomware group called Blackcat breached part of Change Healthcare’s information technology network. UnitedHealth Group isolated and disconnected the affected systems “immediately upon detection” of the threat, according to a filing with the U.S. Securities and Exchange Commission, but the ensuing disruption rocked the health-care sector.

Money stopped flowing while the company’s systems were offline, so a major revenue source for thousands of providers across the U.S. screeched to a halt. Some doctors pulled thousands of dollars out of their personal savings to keep their practices afloat.

“It was and remains the largest and most consequential cyberattack against health care in history,” John Riggi, the national advisor for cybersecurity and risk at the American Hospital Association, told CNBC.

Ransomware is a type of malicious software that blocks victims from accessing their computer files, systems and networks, according to the Federal Bureau of Investigation. Ransomware groups such as Blackcat, which are often based in countries such as Russia, China and North Korea, will deploy this software, steal sensitive data and then demand a payment for its return.

Ransomware attacks within the health-care sector have climbed in recent years, in part because patient data is valuable and relatively easy for cybercriminals to exploit, said Steve Cagle, CEO of the health-care cybersecurity and compliance firm Clearwater.

“It’s been a very lucrative and successful business for them,” Cagle told CNBC. “Unfortunately, we’ll continue to see that type of activity until something changes.”

UnitedHealth Group paid the hackers a $22 million ransom to try to protect patients’ data, then-CEO Witty said during a Senate hearing in May 2024.

In March 2024, UnitedHealth Group launched a temporary funding assistance program to help providers with short-term cash flow.

The program got off to a rocky start, several doctors told CNBC, and the initial deposits did not cover their mounting expenses.

UnitedHealth Group ultimately paid out more than $9 billion to providers in 2024, according to the company’s fourth-quarter earnings report in January.

Witty said in his congressional testimony that providers would only be required to repay the loans when “they, not me, but they confirm that their cash flow is normalized.”

Almost a year later, however, the company is aggressively going after borrowers, demanding they “immediately repay” their outstanding balances, according to documents viewed by CNBC and providers who received funding. Some groups have been asked to repay hundreds of thousands of dollars in a matter of days, according to documents viewed by CNBC.

A spokesperson for Change Healthcare confirmed to CNBC in April that the company has started recouping the loans.

We continue to work with providers on repayment and other options, and continue to reach out to those providers that have not been responsive to previous calls or email requests for more information,” the spokesperson said.

The pressure for repayment drew more ire toward UnitedHealth Group on social media, and some providers told CNBC that dealing with the company was a “very frustrating experience.”

The vast majority of Change Healthcare’s services have been restored over the last year, but three products are still listed as “partial service available,” according to UnitedHealth’s cyberattack response website.

Witty’s departure and the company’s warning about elevated medical costs, combined with the fallout from Thompson’s murder and the Change Healthcare cyberattack, could mean UnitedHealth faces an uphill battle.

UnitedHealth Group appears to be trying to regain the public’s trust. For example, Optum Rx in March announced plans to eliminate prior authorizations on dozens of drugs, easing a pain point for physicians and patients.

But policy changes at UnitedHealth Group and other insurers may not drastically improve care for patients, health insurance industry experts previously told CNBC.

They said there will need to be structural changes to the entire insurance industry, which will require legislation that may not be high on the priority list for the closely divided Congress.

The spotlight on UnitedHealth Group may only grow brighter in the coming months. The trial date for Luigi Mangione, the man facing federal stalking and murder charges in connection with Thompson’s shooting, is expected to be set in December. Mangione has pleaded not guilty to the charges.

This post appeared first on NBC NEWS